Alprostadil


Generic Medicine Info
Contraindications
History of recurrent priapism, sickle cell anaemia or trait, multiple myeloma, leukaemia, thrombocythaemia, polycythaemia, predisposition to venous thrombosis, anatomical penile deformation (e.g. angulation, cavernosal fibrosis, Peyronie's disease, stenosis of distal urethra, severe hypospadias and curvature, balanitis, acute/chronic urethritis), penile implants. Patient for whom sexual activity is inadvisable (e.g. unstable CV or cerebrovascular conditions). Concomitant use w/ other drugs for erectile dysfunction (e.g. phosphodiesterase type 5 (PDE5) inhibitors, papaverine). Neonates w/ resp distress syndrome. Childn (intracavernosal).
Special Precautions
Patient w/ bleeding tendencies, blood-borne and pulmonary diseases, transient ischaemic attacks, CHD, CHF, history of psychiatric disorder or addiction. Pregnancy (use condom barrier if female partner is or may be pregnant). Patient Counselling This drug may cause dizziness, syncope, and hypotension, if affected, do not drive or operate machinery. Monitoring Parameters Monitor for BP, resp and heart rates, temp, degree of penile pain, duration of erection, adequate detumescence after dosing, and signs of infection.
Adverse Reactions
Headache, flushing, hypotension, diarrhoea; pain, haematoma, and ecchymoses at inj site; pain during erection, fibrotic nodules, Peyronie's disease, priapism. Rarely, penile fibrosis. Apnoea, fever, bradycardia, tachycardia, convulsion, oedema, cardiac arrest, hypokalaemia, disseminated intravascular coagulation, cortical proliferation of long bones (childn).
Drug Interactions
Reduced effect w/ sympathomimetics, decongestants, and appetite suppressants. May enhance the effects of antihypertensives, vasoactive drugs, anticoagulants and platelet aggregation inhibitors.
ATC Classification
G04BE01 - alprostadil ; Belongs to the class of drugs used in erectile dysfunction.
C01EA01 - alprostadil ; Belongs to the class of prostaglandins used in cardiac therapy.
Disclaimer: This information is independently developed by CIMS based on alprostadil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in